Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD) medicines. The company's core business involves leveraging the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, aiming to address previously 'undruggable' targets. Founded in 2019, Monte Rosa Therapeutics is headquartered in Boston, Massachusetts, with additional research operations in Basel, Switzerland.

At the heart of Monte Rosa's drug discovery efforts is its proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine. This platform integrates artificial intelligence, machine learning, chemistry, structural biology, and proteomics to identify degradable protein targets and rationally design highly selective MGDs. The company's pipeline is focused on oncology, autoimmune, and inflammatory diseases. Key product candidates include MRT-2359, a GSPT1-directed MGD for MYC-driven tumors such as metastatic castration-resistant prostate cancer; MRT-8102, a NEK7-directed MGD for inflammatory diseases; and MRT-6160, a VAV1-directed MGD for immune-mediated diseases.

Led by CEO Markus Warmuth, M.D., Monte Rosa Therapeutics has established significant strategic collaborations, including a partnership with Roche in October 2023 to discover and develop MGDs for cancer and neurological diseases. In October 2024, the company entered a global exclusive license agreement with Novartis for VAV1 MGDs, including MRT-6160, which involved a $150 million upfront payment and potential milestones up to $2.1 billion. Recent developments include a $300 million public offering in January 2026 to fund pipeline advancement and extend its cash runway into 2029, as well as positive interim Phase 1 data for MRT-8102 and preclinical data for a Cyclin E1 degrader presented in early 2026.